Hoechst Aktiengesellschaft

Boehringer Mannheim Gmbh

Volker Hitzel

Rudi Weyer

Karl Geisen

Werner Pfaff

Gunter Regitz

Walter Aumuller

Helmut Weber

Ernst-Christian Witte

Ruth Heerdt

Manfred Hubner

Karl Muth

Hans Kuhnle

Harald Ritzel

Martin Bickel

Ernold Granzer

Elmar Bosies

Gerhard Rackur

Felix Helmut Schmidt

Karl Giesen

The invention relates to compounds of the formula ##STR1## in which R.sup.1 and R.sup.2 are identical or different and are hydrogen, alkyl, trifluoromethyl, halogen, alkoxycarbonyl, alkoxy or alkanoyl, R.sup.3, R.sup.4 and R.sup.5 are identical or different and are hydrogen, methyl, alkoxy or alkoxyethoxy, and R is hydrogen or a group SR.sup.6, in which R.sup.6 is the lone, unpaired electron of the 12-sulfenyl radical, hydrogen, optionally substituted alkyl, alkenyl, alkynyl, alkanoyl, optionally mono- or poly-substituted benzoyl, fuoryl, phenacyl, phenoxyacetyl, phenylacetyl or another conventional thiol-protective group, and to physiologically acceptable salts thereof, and to processes for their preparation, to their use as a gastric acid secretion inhibitor and to pharmaceutical preparations based on these compounds.

Substituted pyrido (1,2-c)imidazo(1,2-a)benzimidazoles, processes for

Salicylic acid derivatives of the formula I ##STR1## wherein R.sup.1, W, X, Y and Z have the meanings indicated or a physiologically tolerated salt thereof, processes for their preparation, pharmaceutical formulations based on these compounds and their use as antidiabetic agents.

Antidiabetic salicylic acid derivatives

Sulfonylureas of the formula ##STR1## in which Y denotes alkylene having 2-3 C atoms, R denotes alkyl having 1-4 C atoms, R.sup.1 denotes hydrogen, chlorine or methyl, and R.sup.2 denotes alkyl having 3-6 C atoms, cycloalkyl, alkylcycloalkyl, cycloalkylalkyl, cycloalkenyl, alkylcycloalkenyl or cycloalkenylalkyl, each having 5-8 C atoms, and their physiologically tolerated salts, and processes for their preparation and medicaments prepared therefrom.

Sulfonylureas pharmaceutical formulations based on these compounds and

What are disclosed are sulfonyl ureas of the formula ##STR1## in which R.sup.1, X and Y are as defined in the specification, and their physiologically acceptable salts, pharmaceutical formulations on the basis of these compounds, and their use in the treatment of diabetes.

Heterocyclic substituted sulfonyl ureas, and their use

Sulfonylureas of the formula ##STR1## in which ##STR2## R.sup.1, X and Y have the indicated meanings and the physiologically acceptable salts thereof, pharmaceutical preparations on the basis of said compounds and their use in the treatment of diabetes.

Benzenesulfonyl ureas, and pharmaceutical preparations

Sulfonylureas of the formula ##STR1## wherein R.sup.1, X and Y have the indicated meanings, as well as their physiologically acceptable salts, pharmaceutical preparations on the basis of these compounds and their use in the treatment of diabetes.

Thienopyrrolone substituted benezenesulfonylureas and their use

Sulfonylureas of the formula ##STR1## wherein n, R, R.sup.1 and X have the indicated meanings, as well as their physiologically acceptable salts, pharmaceutical preparations on the basis of these compounds and their use for treating diabetes.

Antidiabetic 1-piperidine-sulfonylureas

Sulfonylureas of the formula ##STR1## in which n, R, R.sup.1, X and Y have the indicated meanings and the physiologically acceptable salts thereof, pharmaceutical preparations on the basis of said compounds and their use in the treatment of diabetes.

Sulfonyl ureas and pharmaceutical preparations thereof

Phenylacetic acid derivatives of the formula ##STR1## wherein A is an aryl radical optionally substituted by halogen, trifluoromethyl, alkyl, alkoxy, alkenyloxy, alkoxyalkoxy, alkyl-substituted amino or aryloxy, or a heterocyclic ring system optionally substituted by halogen, alkyl or alkoxy,

Hypoglycaemically and hypolipidaemically active derivatives of

Acyl-aminoalkyl-benzoic acid and derivates thereof show a blood sugar lowering effect upon oral administration and can be used as orally applicable hypoglycemiants.

Benzoic acids, their derivatives and process for preparing them

Benzoic acids of the general formula I ##STR1## in which R, R.sup.1, R.sup.2 and Y have the meanings as mentioned in the following, and which in the form of the free compounds or in the form of the physiologically tolerated salts and esters possess valuable pharmacological properties, processes for preparing them, pharmaceutical preparations containing them, and their use as or in medicaments.

Benzoic acids and process for their preparation

Benzoic acid derivatives of the formula ##STR1## wherein T is hydrogen or halogen, W is a carboxyl group, an ester or salt thereof; X is ##STR2## wherein R.sub.1 is alkyl having from 2 to 8 carbon atoms, aralkyl or phenyl, cycloalkyl, cycloalkylalkyl or alkylcycloalkyl; R.sub.2 is hydrogen or halogen, R.sub.3 is alkyl having from 5 to 8 carbon atoms, aralkyl or phenyl, or cycloalkyl having from 5 to 8 carbon atoms; R.sub.4 is hydrogen or alkyl; Y is a single chemical bond or a hydrocarbon chain having from 1 to 3 carbon atoms; and Z is hydrogen, halogen, alkyl, alkoxy, alkoxyalkoxy or alkenyloxy, have a blood sugar lowering effect and can be used for the treatment of Diabetes mellitus.

Certain nicotinamido-n-benzoic acid derivatives

The invention relates to acylamino(alkyl)benzene derivatives of the general formula ##STR1## in which W represents a group which can be converted into a carboxyl group, or an aldehyde group or an oxymethyl group or their derivatives or also a low molecular weight alkyl group, preferably a methyl group,

Acylamino(alkyl)benzene derivatives and process for preparing them

Benzenesulfonyl ureas of the formula ##STR1## in which R, R.sup.1, X, X.sup.1 and Y have the defined meanings, and the salts thereof, process for preparing these compounds, pharmaceutical preparations containing them and their use for lowering the blood sugar level.

Growing community of inventors

Hofheim am Taunus, Germany

Volker Hitzel